Product Description
CX1942 is an Ampakine that has been specifically designed as an injectable drug product for the treatment of respiratory depression. (Sourced from: http://www.respirerx.com/development/cx1942.html)
Mechanisms of Action: OPR Antagonist
Novel Mechanism: No
Modality: N/A
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: RespireRx
Company Location: GLEN ROCK NJ 07452
Company CEO: Arnold S. Lippa
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Opioid-Related Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|